Literature DB >> 16041045

Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.

Paul J Domanski1, Pratiksha R Patel, Arnold S Bayer, Li Zhang, Andrea E Hall, Peter J Syribeys, Elena L Gorovits, Dawn Bryant, John H Vernachio, Jeff T Hutchins, Joseph M Patti.   

Abstract

We report the humanization and characterization of monoclonal antibody (MAb) T1-2 or tefibazumab, a monoclonal antibody that recognizes clumping factor A expressed on the surface of Staphylococcus aureus. We demonstrate that the binding kinetics of MAb T1-2 is indistinguishable compared to that of its murine parent. Furthermore, MAb T1-2 is shown to enhance the opsonophagocytic uptake of ClfA-coated latex beads, protect against an intravenous challenge in a prophylactic model of rabbit infective endocarditis, and enhance the efficacy of vancomycin therapy in a therapeutic model of established infective endocarditis.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16041045      PMCID： PMC1201235          DOI： 10.1128/IAI.73.8.5229-5232.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  21 in total

1.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Surface protein adhesins of Staphylococcus aureus.

Authors:  T J Foster; M Höök
Journal:  Trends Microbiol       Date:  1998-12       Impact factor: 17.079

3.  Study of Staphylococcus aureus pathogenic genes by transfer and expression in the less virulent organism Streptococcus gordonii.

Authors:  P Stutzmann Meier; J M Entenza; P Vaudaux; P Francioli; M P Glauser; P Moreillon
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Antibody responses in patients with staphylococcal septicemia against two Staphylococcus aureus fibrinogen binding proteins: clumping factor and an extracellular fibrinogen binding protein.

Authors:  P Colque-Navarro; M Palma; B Söderquist; J I Flock; R Möllby
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

5.  Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant.

Authors:  E Josefsson; O Hartford; L O'Brien; J M Patti; T Foster
Journal:  J Infect Dis       Date:  2001-12-03       Impact factor: 5.226

6.  Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System.

Authors:  M J Richards; J R Edwards; D H Culver; R P Gaynes
Journal:  Crit Care Med       Date:  1999-05       Impact factor: 7.598

7.  Clumping factor A mediates binding of Staphylococcus aureus to human platelets.

Authors:  I R Siboo; A L Cheung; A S Bayer; P M Sullam
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

8.  Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998.

Authors:  C A Morin; J L Hadler
Journal:  J Infect Dis       Date:  2001-09-04       Impact factor: 5.226

9.  Expression of Staphylococcus aureus clumping factor A in Lactococcus lactis subsp. cremoris using a new shuttle vector.

Authors:  Y A Que; J A Haefliger; P Francioli; P Moreillon
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

10.  Transcription of clumping factor A in attached and unattached Staphylococcus aureus in vitro and during device-related infection.

Authors:  Christiane Wolz; Christiane Goerke; Regine Landmann; Werner Zimmerli; Ursula Fluckiger
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441
View more
  28 in total

Review 1.  Antistaphylococcal vaccines and immunoglobulins: current status and future prospects.

Authors:  Stan Deresinski
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis.

Authors:  Seth Hetherington; Michele Texter; Eric Wenzel; Joseph M Patti; Laurie Reynolds; Trish Shamp; Suzanne Swan
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

3.  Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine.

Authors:  Casie Kelly-Quintos; Lisa A Cavacini; Marshall R Posner; Donald Goldmann; Gerald B Pier
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Adaptive Immunity Against Staphylococcus aureus.

Authors:  Hatice Karauzum; Sandip K Datta
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

5.  Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia.

Authors:  J John Weems; James P Steinberg; Scott Filler; John W Baddley; G Ralph Corey; Priya Sampathkumar; Lisa Winston; Joseph F John; Christine J Kubin; Rohit Talwani; Thomas Moore; Joseph M Patti; Seth Hetherington; Michele Texter; Eric Wenzel; Violet A Kelley; Vance G Fowler
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 6.  Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.

Authors:  Andreas Ambrosch; Simone Haefner; Edward Jude; Ralf Lobmann
Journal:  Int Wound J       Date:  2011-08-23       Impact factor: 3.315

7.  Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice.

Authors:  Lorena P N Tuchscherr; Fernanda R Buzzola; Lucía P Alvarez; Jean C Lee; Daniel O Sordelli
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

8.  Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A.

Authors:  Kouji Narita; Dong-Liang Hu; Fumiaki Mori; Koichi Wakabayashi; Yoichiro Iwakura; Akio Nakane
Journal:  Infect Immun       Date:  2010-08-02       Impact factor: 3.441

9.  Sortases, Surface Proteins, and Their Roles in Staphylococcus aureus Disease and Vaccine Development.

Authors:  Olaf Schneewind; Dominique Missiakas
Journal:  Microbiol Spectr       Date:  2019-01

Review 10.  Staphylococcus aureus Aggregation and Coagulation Mechanisms, and Their Function in Host-Pathogen Interactions.

Authors:  H A Crosby; J Kwiecinski; A R Horswill
Journal:  Adv Appl Microbiol       Date:  2016-08-04       Impact factor: 5.086
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.